{
    "organizations": [],
    "uuid": "4fee3a801c8b65d95142e31f4e5defd2b14a6e0f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bioxcel-therapeutics-sees-ipo-of-5/brief-bioxcel-therapeutics-sees-ipo-of-5-0-mln-shares-of-common-stock-priced-between-11-00-and-13-00-per-share-idUSFWN1QH131",
    "ord_in_thread": 0,
    "title": "Bioxcel Therapeutics Sees IPO Of 5.0 Mln Shares Of Common Stock Priced Between $11.00 And $13.00 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 27 (Reuters) - Bioxcel Therapeutics Inc:\n* BIOXCEL THERAPEUTICS INC SEES IPO OF 5.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $11.00 AND $13.00 PER SHARE - SEC FILING\n* BIOXCEL THERAPEUTICS INC SAYS INTENDS TO USE ABOUT $25 MILLION OF IPO NET PROCEEDS TO FUND BXCL501 THROUGH PHASE 2 CLINICAL DEVELOPMENT\n* BIOXCEL THERAPEUTICS INC SAYS INTENDS TO USE ABOUT $17 MILLION OF IPO NET PROCEEDS TO FUND BXCL701 THROUGH PHASE 2 CLINICAL DEVELOPMENT Source text: ( bit.ly/2FA1V8J ) Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-02-27T21:09:00.000+02:00",
    "crawled": "2018-02-27T15:21:21.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "bioxcel",
        "therapeutic",
        "inc",
        "bioxcel",
        "therapeutic",
        "inc",
        "see",
        "ipo",
        "million",
        "share",
        "common",
        "stock",
        "priced",
        "per",
        "share",
        "sec",
        "filing",
        "bioxcel",
        "therapeutic",
        "inc",
        "say",
        "intends",
        "use",
        "million",
        "ipo",
        "net",
        "proceeds",
        "fund",
        "bxcl501",
        "phase",
        "clinical",
        "development",
        "bioxcel",
        "therapeutic",
        "inc",
        "say",
        "intends",
        "use",
        "million",
        "ipo",
        "net",
        "proceeds",
        "fund",
        "bxcl701",
        "phase",
        "clinical",
        "development",
        "source",
        "text",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}